Article Text
Letter
Adalimumab use in pregnancy
Statistics from Altmetric.com
Infliximab, a chimeric antibody to tumour necrosis factor alpha (TNF-α), has demonstrated efficacy for the induction and maintenance of remission in patients with Crohn’s disease.1,2 Antibodies to the chimeric component of infliximab can lead to infusion reactions and possible loss of response.3 A human recombinant monoclonal antibody to TNF-α, adalimumab, has recently demonstrated safety and efficacy for induction of remission in Crohn’s disease.4 It has also been effective in patients who have lost response to infliximab.5 Currently, this drug is FDA approved for the treatment of rheumatoid arthritis but it is being administered off label to patients with Crohn’s disease who …